Compare AbCellera Biologics Inc (ABCL) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Direxion Daily Semiconductor Bear 3X Shares trades at $4.56. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals.
| ABCL | SOXS | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $160.60 |
52-Week Low | $2.78 | $3.25 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, is trading at $4.17, down 7.54% over the past 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. A 1-for-10 stock split is scheduled for July 15, 2026. Recent news highlights the ETF's role in betting against the semiconductor sector amid a historic AI-driven chip rally, with SOXS down 88% over six months as of May 2026.
The outlook for SOXS remains highly risky due to its inverse leveraged structure and the strong bullish trend in semiconductors. Investment opportunity exists solely for tactical, short-term traders seeking to profit from potential sector pullbacks, but risks of significant losses are elevated if the rally persists. Long-term investors should avoid due to volatility decay and structural drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
